2SEVENTY BIO, INC.

(TSVT)
  Report
Delayed Nasdaq  -  05/19 04:00:01 pm EDT
11.78 USD   +3.61%
05/17Morgan Stanley Adjusts 2seventy bio's Price Target to $31 from $36, Keeps Overweight Rating
MT
05/122SEVENTY BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/122seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

2Seventy Bio Working With Novo Nordisk to Develop Potential Gene-Editing Treatment for Hemophilia A

01/06/2022 | 07:40am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
2SEVENTY BIO, INC. 3.61% 11.78 Delayed Quote.-54.04%
NOVO NORDISK A/S 0.97% 738.1 Delayed Quote.-0.56%
All news about 2SEVENTY BIO, INC.
05/17Morgan Stanley Adjusts 2seventy bio's Price Target to $31 from $36, Keeps Overweight Ra..
MT
05/122SEVENTY BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
05/122seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/122seventy bio Reports First Quarter Financial Results and Recent Operational Progress
BU
05/12Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $8.4M
MT
05/02Goldman Sachs Starts 2seventy Bio at Buy With $26 Price Target
MT
04/292SEVENTY BIO, INC. : Other Events (form 8-K)
AQ
04/292seventy bio, Inc. Enters into the First Amendment to the License Agreement
CI
04/292Seventy Bio Files for Potential Secondary Offering
MT
04/082SEVENTY BIO : Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting ..
PU
More news
Analyst Recommendations on 2SEVENTY BIO, INC.
More recommendations
Financials (USD)
Sales 2022 81,3 M - -
Net income 2022 -240 M - -
Net cash 2022 213 M - -
P/E ratio 2022 -1,50x
Yield 2022 -
Capitalization 443 M 443 M -
EV / Sales 2022 2,83x
EV / Sales 2023 1,45x
Nbr of Employees 437
Free-Float 98,5%
Chart 2SEVENTY BIO, INC.
Duration : Period :
2seventy bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 2SEVENTY BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 11,78 $
Average target price 33,20 $
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Nick Leschly President & Director
William Denise Baird Chief Financial & Accounting Officer
Daniel S. Lynch Chairman
Philip D. Gregory Chief Scientific Officer
Steven H. Bernstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
2SEVENTY BIO, INC.-54.04%443
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418